Skip to content
lifestyle.briefmobile.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Lexeo Therapeutics
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy
August 5, 2026
Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia
June 17, 2026
Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia
June 15, 2026
Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
May 21, 2026
Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights
May 11, 2026
Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
May 9, 2026
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
May 5, 2026
Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference
May 1, 2026
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February
March 9, 2026